Published in
Esmo Open, Esmo Open, 6(5), p. e001079, 2020
DOI: 10.1136/esmoopen-2020-001079
Links
Tools
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Journal article published in 2020 by
Laurence Albiges 
,
Nizar M. Tannir,
Mauricio Burotto,
David McDermott,
Elizabeth R. Plimack,
Philippe Barthélémy,
Camillo Porta ,
Thomas Powles,
Frede Donskov,
Saby George,
Christian K. Kollmannsberger,
Howard Gurney,
Marc-Oliver Grimm,
Yoshihiko Tomita,
Daniel Castellano
and other authors.
,
Nizar M. Tannir,
Mauricio Burotto,
David McDermott,
Elizabeth R. Plimack,
Philippe Barthélémy,
Camillo Porta ,
Thomas Powles,
Frede Donskov,
Saby George,
Christian K. Kollmannsberger,
Howard Gurney,
Marc-Oliver Grimm,
Yoshihiko Tomita,
Daniel Castellano
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Data provided by 